Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma

16Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Hepatocellular carcinoma is one of the most lethal cancers in the United States. Early detection of the disease is crucial for reducing the mortality of this malignancy. Recently, we identified a panel of fusion genes present in several types of human cancers, including hepatocellular carcinoma. Among 8 fusion genes, MAN2A1-FER, TRMT11-GRIK2 and CCNH-C5orf30 appear most frequently in hepatocellular carcinoma samples. In this study, we showed that the fusion transcripts of MAN2A1-FER, CCNH-C5orf30 and SLC45A2-AMACR were detected in the serum samples of liver cancer patients as circulating cell-free RNA. The distributions of these gene fusion RNA fragments largely matched those of the primary HCC samples. In contrast, the sera of all healthy individuals free of human malignancies were shown to be negative for these fusion genes. These results suggest that gene fusion RNA is frequently shed from liver cancer cells. The detection of serum cell-free fusion transcripts may provide a new approach to aid in the diagnosis, follow-up or therapy of liver cancers.

Cite

CITATION STYLE

APA

Yu, Y. P., Tsung, A., Liu, S., Nalesnick, M., Geller, D., Michalopoulos, G., & Luo, J. H. (2019). Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma. Oncotarget, 10(36), 3352–3360. https://doi.org/10.18632/oncotarget.26918

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free